Gylden Pharma

Gylden is a clinical-stage, privately held biotechnology company, headquartered in Abingdon, UK, with an operating subsidiary in Doylestown, Pennsylvania and GMP manufacturing facilities in Milton Park, Oxfordshire, UK, and Fremont, CA, USA. The Company is pioneering the development of 100% synthetic, T cell-priming vaccines/immunotherapies designed to mimic the bodys natural cellular immune response to destroy and to clear pathogen-infected cells to protect against some of the worlds most urgent health threats. The candidates are designed for delivery via novel skin immunisation into the epidermal layer, aiming to ease the burden and logistics of traditional preventative methods. Gyldens first indications pursued are against infectious diseases: [i] including core candidates for Betacoronaviruses, Dengue Fever and Universal Influenza (including Pandemic Influenza), as well as [ii] intra-cellular bacterial infectious disease. Additional products include MAP-based products for a nu...